Первичная гиперхолестеринемия IIa и IIb типа (при неэффективности диетотерапии у пациентов с повышенным риском развития коронарного атеросклероза), комбинированная гиперхолестеринемия и гипертриглицеридемия, гиперлипопротеинемия, не поддающаяся коррекции специальной диетой и физической нагрузкой. Профилактика инфаркта миокарда (для замедления прогрессирования коронарного атеросклероза), инсульта и преходящих нарушений мозгового кровообращения.

SIMVASTATIN

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simovil is indicated to: Reduce the risk of total mortality by reducing coronary death; Reduce the risk of non-fatal myocardial infarction; Reduce the risk for undergoing myocardial revascularization procedures; Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simovil is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simovil therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia): Simovil is indicated for the treatment of patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia ( Fredrickson type III hyperlipidemia). Simovil is indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).